Alkanolamide Composition Inhibiting Langerhans Cell Migration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current dermatological treatments fail to effectively inhibit the migration of Langerhans cells, dermal dendrocytes, and monocytes, which contributes to allergic and inflammatory skin reactions, as these cells play a central role in immune responses and their migration is not fully understood or controlled.
Innovation Solution
A composition containing alkanolamides, potentially combined with matrix metalloprotease inhibitors, PKC inhibitors, anti-inflammatory agents, immunosuppressors, ion chelating agents, oxazolidinones, and derivatives of carbamic acid, which are applied topically to inhibit the migration of Langerhans cells and other immune cells, thereby reducing allergic and inflammatory reactions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional dermatological treatments are used, then general skin protection is provided, but migration of Langerhans cells and other immune cells cannot be effectively inhibited
Solution Approach 1:
The patent employs composite materials by combining alkanolamides with matrix metalloprotease inhibitors, PKC inhibitors, and other active compounds in a single topical composition. This multi-component formulation addresses the limitation of conventional single-agent treatments by integrating multiple mechanisms of action to effectively inhibit immune cell migration while maintaining skin health.
Solution Approach 2:
The invention utilizes parameter changes by modifying the chemical structure and properties of alkanolamides (with general formula where R1-R6 represent various hydrocarbon groups) to optimize their effectiveness in inhibiting immune cell migration. The specific selection of hydrocarbon chains and functional groups allows tuning of the compound's affinity for target enzymes and cells.
2Object-affected harmful factors
If alkanolamides are used to inhibit Langerhans cell migration, then allergic and inflammatory reactions are reduced, but the mechanism of action is not fully understood
Solution Approach 1:
The patent introduces intermediary compounds (matrix metalloprotease inhibitors, PKC inhibitors) that act as mediators between the alkanolamides and the immune cells. These intermediaries help elucidate the mechanism by blocking specific enzymatic pathways, thereby reducing allergic and inflammatory reactions while providing insight into the migration process.
3Adaptability or versatility
If multiple compounds are combined in the composition, then effectiveness against various skin pathologies is improved, but formulation complexity increases
Solution Approach 1:
The patent applies universality by designing a multi-functional composition where alkanolamides and associated compounds can address multiple skin pathologies simultaneously (atopic eczema, psoriasis, contact dermatitis, seborrheic dermatitis). The formulation is designed to work across different inflammatory and allergic conditions through shared cellular targets.
Solution Approach 2:
The invention merges multiple therapeutic agents (alkanolamides, matrix metalloprotease inhibitors, PKC inhibitors, anti-inflammatory agents, immunosuppressors, ion chelating agents, oxazolidinones, carbamic acid derivatives, and oxazolines) into a single topical composition, consolidating multiple treatment functions into one application.
Data Source
AI summary
The invention concerns a composition containing at least an alkanolamide, optionally combined with at least a compound such as a metalloprotease inhibitor, a PKC inhibitor, an anti-inflammatory agent, a soothing agent, an immunosuppressor, an ion chelating agent, an oxazolin, an oxazolidinone and a carbamic acid derivative. The invention also concerns the use of such a composition as medicine, in particular its use for preventing or treating skin pathologies of allergic and/or inflammatory and/or irritative origin or resulting from a danger signal. The invention further concerns a method for cosmetic treatment of sensitive, irritated, intolerant, allergy-prone, ageing skin and/or mucosa exhibiting skin barrier disorder, or exhibiting non-pathological immunologic imbalance, which consists in applying such a composition on the skin and/or mucosa.